- ISIN
- US28617K1016
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 17, 2014
Highlights
- Market Cap
- $444.08M
- Enterprise Value
- $438.85M
- EPS (TTM)
- -$0.91
- EBITDA (TTM)
- -$84.86M
- Year Range
- $1.35 - $4.60
- Target Price
- $5.00
- ROA (TTM)
- -53.28%
- ROE (TTM)
- -174.58%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ELDN Performance Chart
Eledon Pharmaceuticals Inc (ELDN) is up 161.6% since the beginning of the year. At $4 per share, ELDN is trading 14.1% below its 52-week high of $5. Investors who bought $1,000 worth of ELDN shares 5 years ago would now be looking at an investment worth $502.
Loading charts...
Returns By Period
Eledon Pharmaceuticals Inc (ELDN) has returned 161.59% so far this year and 51.92% over the past 12 months. Over the last ten years, ELDN has returned -41.77% per year, falling short of the S&P 500 Index benchmark, which averaged 13.71% annually.
Eledon Pharmaceuticals Inc
- 1D
- 3.67%
- 1M
- 1.54%
- YTD
- 161.59%
- 6M
- 159.87%
- 1Y
- 51.92%
- 3Y*
- 39.98%
- 5Y*
- -12.88%
- 10Y*
- -41.77%
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
ELDN Monthly Returns History
Based on dividend-adjusted daily data since Sep 17, 2014, ELDN's average daily return is -0.02%, while the average monthly return is -0.16%.
Historically, 41% of months were positive and 59% were negative. The best month was Jan 2019 with a return of +168.8%, while the worst month was Jul 2016 at -77.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.
On a daily basis, ELDN closed higher 44% of trading days. The best single day was Sep 15, 2020 with a return of +192.9%, while the worst single day was Jul 26, 2016 at -78.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 45.70% | 19.09% | 17.56% | 18.18% | 4.67% | 3.67% | 161.59% | ||||||
| 2025 | 9.71% | -8.19% | -18.31% | -6.78% | -5.06% | -9.67% | 16.24% | -17.78% | -0.00% | 66.80% | -62.27% | -7.36% | -63.35% |
| 2024 | -1.11% | 1.12% | 14.44% | 16.02% | 15.06% | -4.00% | 11.36% | -4.42% | -11.39% | 86.75% | 0.22% | -11.59% | 128.89% |
| 2023 | 45.61% | -28.92% | 0.00% | -11.02% | 0.00% | -34.76% | 0.73% | 10.14% | -9.87% | 13.87% | -26.28% | 56.52% | -21.05% |
| 2022 | -8.16% | -12.84% | 11.61% | -22.34% | 4.25% | -23.51% | 23.36% | 24.58% | -26.40% | -12.68% | 1.24% | -6.56% | -48.30% |
| 2021 | -3.70% | 8.36% | -33.42% | -6.54% | -4.80% | -16.91% | -17.95% | 28.20% | -25.72% | -19.09% | -2.20% | -9.82% | -71.36% |
Benchmark Metrics
Eledon Pharmaceuticals Inc has an annualized alpha of -13.58%, beta of 0.71, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 17, 2014.
- This stock participated in 141.77% of S&P 500 Index downside but only -78.68% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -13.58%
- Beta
- 0.71
- R²
- 0.01
- Upside Capture
- -78.68%
- Downside Capture
- 141.77%
Return for Risk
Risk / Return Rank
ELDN ranks 63 for risk / return — better than 63% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Eledon Pharmaceuticals Inc (ELDN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ELDN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.20 | ||
| Sortino ratioReturn per unit of downside risk | -1.13 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.32 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | 0.77 | 2.46 | -1.69 |
| Martin ratioReturn relative to average drawdown | 1.39 | 10.92 | -9.53 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Eledon Pharmaceuticals Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Eledon Pharmaceuticals Inc was 99.97%, occurring on Nov 29, 2023. The portfolio has not yet recovered.
The current Eledon Pharmaceuticals Inc drawdown is 99.90%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -99.97%Nov 2023 | 9y 2mo | — | 11y 9moSep 2014 - now |
Drawdown Indicators
| ELDN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.97% | -56.78% | -43.19% |
Max Drawdown (1Y)Largest decline over 1 year | -68.12% | -9.10% | -59.02% |
Max Drawdown (3Y)Largest decline over 3 years | -73.77% | -18.90% | -54.87% |
Max Drawdown (5Y)Largest decline over 5 years | -86.76% | -25.43% | -61.33% |
Max Drawdown (10Y)Largest decline over 10 years | -99.88% | -33.92% | -65.96% |
Current DrawdownCurrent decline from peak | -99.90% | -3.21% | -96.69% |
Average DrawdownAverage peak-to-trough decline | -92.01% | -10.71% | -81.30% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 37.55% | 2.04% | +35.51% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Eledon Pharmaceuticals Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Eledon Pharmaceuticals Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ELDN in comparison with other companies in the Biotechnology industry. Currently, ELDN has a P/B value of 10.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ELDN
Add Eledon Pharmaceuticals Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ELDN